Tamoxifen is a non-steroidal, selective estrogen receptor modulator (SERM) used in the treatment of all the stages of breast cancer patients at all ages. Recent evidences showed that tamoxifen could induce cancers which might be a consequent result for chromosomal aberrations in rats. For investigating the chromosomal aberrations induced by tamoxifen treatment, pregnant female rats (four rats per treatment) received tamoxifen orally at dose 0 and 20 mg/ kg b. wt. at different periods. Animals were injected (ip.) with colchicine at 1.5 hr prior sacrifice. Rats were sacrificed 24hr after last treatment. bone marrow cells where collected, then the cells were prepared for karyotype evaluation. 50 well spread metaphase plates were examined per animal. Tamoxifen induced significant increases in the frequencies of structural chromosomal aberrations, like gaps, Centric fragments, dicentirc chromosomes, centric separation and centric fusions in the bone marrow metaphases. However, tamoxifen did not elevate the averages of numerical chromosomal aberrations than the averages of control level. Moreover, a significant increase in the mitotic activity of the bone marrow cells was observed after tamoxifen treatment. The present study proved the clastogenic and the spindle poisoning action of tamoxifen. Consequently, risks against benefits should be carefully evaluated when tamoxifen is used as a therapy of choice on humans.
Introduction
During the 1960's, Imperial Chemical Industry (ICI) 
2006).
The metabolism of tamoxifen is complex and the major metabolites are 4-hydroxy tamoxifen and N-desmethyl tamoxifen that are not reactive towards DNA. It has been shown that the major mechanism of carcinogenicity of tamoxifen in the rat is through the production of α-hydroxytamoxifen to a genotoxic DNA-binding species (Boocock et al., 1999). The carcinogenicity of tamoxifen was evident in human endometrium, and it might be carcinogenic in other tissues, such as the liver and the gut (Fisher et al., 1994) . Beland et al.
(1999) observed an extensive hepatic DNA adduct are formed by tamoxifen, they stated that these adducts might result from α-hydroxy-tamoxifen and that DNA adducts could be detected in the uterine DNA from rats treated with tamoxifen.
The aim the present study is to investigate the chromosomal aberrations induced by tamoxifen in the bone marrow cells of adult female pregnant rats before mating and during pregnancy. Such genetic damage may reflect the reduction in the reproductive ability of the treated females or affect their offspring.
Materials and Methods

Animals.
Fertile adult virgin female albino rats, purchased from the National Organization for Drug Control And Research (NODCAR) at 6 Abou Hazem St., Pyramids Avenue, Giza, Egypt. The rats were acclimatized for one week at the animal house before the experimentation. The rats were cared humanly and exposed to regular dark/light cycles every 12 hr and good ventilation at temperature 20-22˚C. Commercial balanced diet pellets and water were provided ad libitum.
Tamoxifen Exposure.
Tamoxifen is manufactured by AstraZeneca, UK and purchased under the trade name Nolvadex. Tamoxifen is dissolved in dist. sterile water and administrated as oral suspension through gastric gavage. The females were treated daily with 20 mg/kg b.wt. of tamoxifen orally.
Animal Grouping.
Animals were grouped into 4 groups each of 4 females. The first group (control group) included female animals received dist. water daily. Group (2) 
Chromosome aberration test
Female rats from the control and the tamoxifen-treated groups were intraperitoneally injected with colchicine 1.5 hr prior to sacrifice ( 
Mitotic index
The mitotic index was determined as a measure of cytotoxicity. Mitotic index is counted as the number of dividing cells at any mitotic stage per 1000 cells per animal (Walker, 1954).
Statistical analysis.
One way ANOVA was performed using SPSS software version 10 to determine the significant difference between the treated groups and the control group, the significance values were calculated at P value ≤0.01.
Results and Discussion.
The investigations for chromosomal aberrations were carried out on 50 metaphase 
Results
Chromosomal aberration assay
Numerical chromosomal aberrations (aneuploid metaphases) appeared in the form of metaphases with chromosomal number less (hypodiploid metaphases) or more (hyperdiploid metaphases) than the 2n number that equals to 42 chromosomes (Fig. 1) . The hypodiploid metaphases ranged from 7 to 9 metaphases per 200 examined metaphases. The recorded aneuploidy metaphases were less than 10 % and did not have a constant chromosome number.
So, it is useless to construct karyotype to determine the frequently missing or extra chromosome(s). In addition, the aneuploid metaphases averages were not significantly different in treated groups than the control group.
Structural chromosomal aberrations were observed in the form of chromosomes with missing arm piece (deletions), acentric chromosomal fragment(a piece of chromosome without centromere), chromatid gap (a chromosome arm with unstained area, and it's width is less than the chromatid diameter), chromatid break (a chromatid arm with separated unaligned piece), centromeric separation (the two chromatid arms were separated at the centromere region) and dicentric chromosomes (a chromosome appeared as having two centromere regions. The previously mentioned chromosomal aberrations are presented in figure (2).
The results of structural chromosomal aberrations were summarized in table (1) In group (4), tamoxifen induced a significant increase (P≤ 0.01) in an average of 11 ± 1.15 chromosomal aberrations / 50 metaphases / animal, when compared with those of the control group (1).
1.2. Mitotic index
From Table (1) and figure (4), a clearly significant reduction (P≤0.01) in the percentages of mitotic activity of rat bone marrow cells was observed in the tamoxifen treated groups (2), (3) and (4) compared to the control group. Where, the percentages were, 16.4, 10.35, 9.92 and 9.67 in the control group (1), group (2), group (3) and group (4), respectively. 
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Discussion
In the present study, the administration of 20 mg/kg/day of tamoxifen for 21 days before mating (group 2) induced non-significant differences in the frequencies of total chromosomal aberrations in bone marrow cells. While, administration of 20 mg/kg/day of tamoxifen during pregnancy starting from the 7 th day of gestation (group 3 and 4) induced significant increase (P≤ 0.001) in the frequency of total chromosomal aberrations in the bone marrow cells. Statistically significant increase (P≤ 0.01) in centric fusion and gaps was observed in the groups treated with tamoxifen during pregnancy. The chromosomal aberrations induced by TAM were previously reported by Vijayalaxmi and Rai, (1996) . They 
Conclusion
The present study performed on pregnant rats indicates that tamoxifen alters the structure of chromosomes, increases the incidence of chromosomal aberrations. Careful assessment of the risks as well as the benefits of chronic tamoxifen administration should be considered in using this drug during pregnancy. The relatively high frequency of foetal congenital abnormalities indicated by previous studies suggests that a reliable birth control method must be taken during tamoxifen treatment. Also, mothers who are planing to become pregnant must stop tamoxifen treatment for a recovery period. 
